Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.

From Baxter International Inc. 26 Feb 2013

High-level results from AstraZeneca’s naloxegol Phase III trial on opioid-induced constipation

AstraZeneca today announced high-level results from KODIAC-08, an open-label, randomised, 52-week, long-term safety trial of naloxegol versus usual care (UC) in patients with non-cancer related pain and opioid-induced constipation (OIC). UC was defined as the investigator's choice of an existing laxative treatment regimen for OIC.

26 Feb 2013

Complementary medicine risks: an interview with Dr Andrew Boyden, NPS MedicineWise

Complementary medicines include products containing herbs, vitamins, minerals, nutritional supplements, homoeopathic medicines, certain aromatherapy products and traditional Chinese medicines. For this reason they are also called herbal, natural or alternative medicines.

26 Feb 2013

LINX device may help relieve chronic heartburn symptoms

Clinical trial results published in the New England Journal of Medicine this week offer additional evidence that a new device may help relieve chronic heartburn symptoms that standard treatment cannot. The Keck Medical Center of USC was one of 14 U.S. and European medical centers to test the device prior to its March 2012 approval by the U.S. Food and Drug Administration.

26 Feb 2013

Bayer receives FDA approval for Stivarga to treat advanced gastrointestinal stromal tumors

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease.

26 Feb 2013

Dana-Farber launches iPhone app that helps fight cancer

Dana-Farber Cancer Institute has launched a free, easy-to-use iPhone app that provides recipes and nutrition information that can be searched by cancer patients in accordance with their needs.

25 Feb 2013

GLP-1 may increase risk of hospitalization for people with acute pancreatitis

People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report.

25 Feb 2013

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.

23 Feb 2013

Scopolamine can help boost effectiveness of exposure therapy for anxiety disorders

The drug scopolamine has been used to treat a variety of conditions, including nausea and motion sickness. A new study by UCLA life scientists suggests that it may also be useful in treating anxiety disorders.

22 Feb 2013

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen, immune globulin intravenous [human].

21 Feb 2013

NIAID-funded Phase I trial to evaluate two related candidate vaccines against shigellosis

Researchers have launched an early-stage human clinical trial of two related candidate vaccines to prevent infection with Shigella, bacteria that are a significant cause of diarrheal illness, particularly among children.

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Study investigates whether music therapy reduces stress in cancer patients

A Saint Louis University Cancer Center pilot study is investigating whether music affects the health of cancer patients by soothing them and making them less anxious.

19 Feb 2013

FDA approves Novartis’ Zortress to prevent organ rejection after liver transplantation in adults

Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant.

16 Feb 2013

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Genzyme, a Sanofi company, today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, its investigational oral therapy for Gaucher disease type 1.

15 Feb 2013

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today the U.S. commercial launch of UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

14 Feb 2013

Scopolamine may also be possible treatment for anxiety disorders

However, scopolamine is re-emerging as an antidepressant, with recent studies showing that scopolamine can rapidly improve mood in depressed patients. In addition, in a new study published in Biological Psychiatry this month by Dr. Moriel Zelikowsky and colleagues at the University of California, Los Angeles, it may also be a possible treatment for anxiety disorders.

13 Feb 2013

Preemptive treatment effective for hyperemesis gravidarum and severe morning sickness

`In a study to be presented on February 14 between 1:15 p.m., and 3:30 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in San Francisco, California, researchers will present data showing the effectiveness of preemptive treatment for hyperemesis gravidarum and severe morning sickness.

13 Feb 2013

Tips on avoiding a Valentine's Day Headache

February 14 is right around the corner, and no one wants to spend Valentine's day, or the day after, with a severe headache and some of its accompaniments – nausea, vomiting, sensitivity to light and sound. And you certainly don't want your gift to be the culprit in producing a headache.

12 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Nausea News and Research

Further Reading

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

High-level results from AstraZeneca’s naloxegol Phase III trial on opioid-induced constipation

Complementary medicine risks: an interview with Dr Andrew Boyden, NPS MedicineWise

LINX device may help relieve chronic heartburn symptoms

Bayer receives FDA approval for Stivarga to treat advanced gastrointestinal stromal tumors

Dana-Farber launches iPhone app that helps fight cancer

GLP-1 may increase risk of hospitalization for people with acute pancreatitis

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

Scopolamine can help boost effectiveness of exposure therapy for anxiety disorders

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

NIAID-funded Phase I trial to evaluate two related candidate vaccines against shigellosis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Study investigates whether music therapy reduces stress in cancer patients

FDA approves Novartis’ Zortress to prevent organ rejection after liver transplantation in adults

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Scopolamine may also be possible treatment for anxiety disorders

Preemptive treatment effective for hyperemesis gravidarum and severe morning sickness

Tips on avoiding a Valentine's Day Headache

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News